MOTS-c
Also known as: Mitochondrial ORF of the 12S rRNA Type-C, Mitochondrial-Derived Peptide
What Is MOTS-c?
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded by mitochondrial DNA — not nuclear DNA, which makes it fundamentally different from most peptides in our database. It was discovered in 2015 by Changhan Lee and colleagues at the USC Leonard Davis School of Gerontology and is one of a small class of molecules called mitochondrial-derived peptides (MDPs).
MOTS-c has generated significant scientific interest because of what it represents: a signaling molecule that allows mitochondria to communicate with the rest of the cell and body about metabolic status. In animal models, it has been described as an “exercise mimetic” — exogenous MOTS-c treatment produced metabolic improvements in mice that resemble the benefits of physical exercise.
The excitement is real. The clinical evidence is not. No human clinical trials of exogenous MOTS-c have been conducted. Everything we know about MOTS-c’s therapeutic potential comes from rodent studies and observational measurements of endogenous MOTS-c levels in humans. The grey market has outrun the science by years.
How It Works
MOTS-c operates through a pathway unlike any other peptide in our database:
Mitochondrial-nuclear communication: When cellular metabolic stress occurs (exercise, nutrient deprivation, energy deficit), mitochondria produce and release MOTS-c. The peptide translocates from mitochondria to the cytoplasm and then to the cell nucleus, where it influences gene expression through antioxidant response elements (AREs). This is called “retrograde signaling” — information flowing from mitochondria back to the nucleus.
AMPK activation: MOTS-c’s primary mechanism involves activating AMP-activated protein kinase (AMPK), the cell’s master energy sensor. It does this indirectly by inhibiting the folate-methionine cycle, which blocks de novo purine biosynthesis, leading to accumulation of AICAR (an endogenous AMPK activator). This pathway is similar to how metformin works, leading to the “exercise mimetic” label.
Downstream effects in animal models: Enhanced glucose utilization, increased fat oxidation, improved insulin sensitivity, reduced fat accumulation, increased brown fat activation, and improved mitochondrial respiration.
Exercise response: In healthy young men (N=10), a single bout of exercise on a stationary bike increased skeletal muscle MOTS-c levels 11.9-fold — one of the strongest exercise-responsive peptide signals documented. Circulating MOTS-c levels also increase with exercise. This observation supports the idea that MOTS-c mediates some of the metabolic benefits of exercise.
What the Research Actually Shows
Animal Data
The animal evidence is compelling but must be interpreted with the standard caveat that metabolic mouse models frequently fail to translate to humans.
Lee C et al. (Cell Metab, 2015;21(3):443–454): The discovery paper. Intraperitoneal MOTS-c treatment prevented high-fat diet-induced obesity and insulin resistance in mice. MOTS-c activated AMPK via the folate-AICAR pathway, enhanced glucose utilization, and improved metabolic homeostasis. This paper established MOTS-c as a bona fide metabolic regulator.
Reynolds JC et al. (Nat Commun, 2021;12:470): The exercise mimetic paper. Demonstrated that skeletal muscle MOTS-c increases dramatically with exercise in young men (observational). In mice, exogenous MOTS-c improved physical performance in both young and aged animals. Aged mice (23.5 months — equivalent to ~70 human years) showed improved treadmill endurance, grip strength, and gait quality with MOTS-c treatment.
Lu H et al. (Int J Mol Sci, 2019;20(10):2456): MOTS-c increased thermogenic activation in brown adipose tissue, suggesting enhanced energy expenditure.
Ovariectomized mouse model: MOTS-c treatment (5 mg/kg i.p. for 5 weeks) reduced fat accumulation in white adipose tissue and liver while increasing brown fat activation and improving insulin sensitivity — a model relevant to post-menopausal metabolic dysfunction.
Human Observational Data
No interventional human trials exist. The human data is limited to observations about endogenous MOTS-c levels:
Ramanjaneya M et al. (Front Endocrinol, 2019): Circulating MOTS-c levels are lower in individuals with type 2 diabetes compared to healthy controls. This correlation suggests metabolic relevance but does not demonstrate that exogenous administration would be therapeutic.
Ethnic variation: A polymorphism in the mitochondrial gene encoding MOTS-c (m.1382A>C) is found predominantly in East Asian populations and has been associated with increased diabetes risk, suggesting population-level metabolic effects of MOTS-c variation.
Exercise-induced changes: Multiple small observational studies have measured MOTS-c responses to exercise in healthy humans, confirming that endogenous MOTS-c production increases with physical activity.
MOTS-c is among the most scientifically interesting peptides in our database — the concept of mitochondrial-derived exercise mimetics is genuinely novel. The animal data is published in high-impact journals (Cell Metabolism, Nature Communications). But zero human interventional trials have been conducted. No established human dose exists. Delivery challenges (low bioavailability, short half-life, tendency to persist at injection site) have stalled clinical development. Evidence level: Animal Only.
What’s Missing
- No human clinical trials — not Phase I, not Phase II, nothing. Zero
- No established human dose — animal studies use highly variable doses (0.5–50 mg/kg) with no convergence on optimal dosing
- Severe delivery challenges: Low bioavailability, poor stability, short half-life, and tendency to persist at injection site rather than distribute systemically. These are identified as the primary barriers to clinical translation
- No pharmacokinetic data in humans — we do not know what happens to injected MOTS-c in the human body
- Unknown safety profile beyond endogenous production levels — exogenous administration of a mitochondrial signaling molecule at supraphysiological doses could have unanticipated effects
Safety Profile
Unknown. No human interventional safety data exists. The only safety signal comes from observational data showing that endogenous MOTS-c is a normal component of human biology and varies naturally with exercise, age, and metabolic status.
Theoretical concerns: MOTS-c affects AMPK — a master metabolic regulator involved in cell growth, autophagy, inflammation, and mitochondrial biogenesis. Chronic supraphysiological AMPK activation could have consequences that short-term animal studies would not detect. MOTS-c also regulates immune cell function, including T-cell differentiation — the implications of exogenous administration on immune homeostasis are entirely unknown.
Legal and Regulatory Status
FDA: Category 2 — MOTS-c cannot be legally compounded by 503A or 503B pharmacies. The FDA determined it presents “significant safety risks” based on the complete absence of human clinical data.
WADA: Prohibited under S0 (Non-Approved Substances) as an unapproved, non-clinically-validated substance. USADA has specifically addressed MOTS-c in its educational materials.
Grey-market availability: Available from research chemical vendors, typically as lyophilized powder for injection. Given the documented stability and delivery challenges in the scientific literature, the actual bioactivity of grey-market MOTS-c products is questionable.
Common Vendor Claims vs. Reality
| What vendors say | What the evidence shows |
|---|---|
| ”Exercise in a bottle” | Animal data supports exercise-mimetic effects in mice. No human trial has tested this |
| ”Anti-aging peptide” | MOTS-c levels decline with age and aged mice benefit from treatment — but no human anti-aging study exists |
| ”Improves insulin sensitivity” | Demonstrated in mice. Not tested in human clinical trials |
| ”Burns fat and builds muscle” | Mouse body composition improvements documented. No human body composition data exists |
| ”Clinically proven” | False — no clinical trials of any kind have been conducted |
| ”Natural — your body makes it” | Your body does produce endogenous MOTS-c. Injecting supraphysiological doses of any endogenous peptide is not the same as natural production |
The Bottom Line
MOTS-c represents one of the most scientifically promising — and most clinically premature — peptides on the grey market. The underlying biology is published in top-tier journals. The concept of mitochondrial-derived exercise mimetics is novel and important. The animal data is robust.
But there is literally zero human interventional evidence. No clinical trial. No established dose. No pharmacokinetic data. No safety data. No delivery solution for the well-documented bioavailability problems. The scientific community itself has identified delivery challenges as the primary barrier to clinical translation — and the grey market has simply bypassed this barrier by selling injectable MOTS-c without addressing whether it actually reaches its target tissues when injected subcutaneously in humans.
If MOTS-c does what the animal data suggests, it could be transformative. But “could be” and “is” are separated by clinical trials that have not yet begun. Injecting a grey-market MOTS-c product is not participating in science — it is speculating with a peptide that the researchers who discovered it have not yet validated for human use.
Lee C et al., Cell Metab, 2015;21(3):443–454; Reynolds JC et al., Nat Commun, 2021;12:470; Ramanjaneya M et al., Front Endocrinol, 2019;10:331; Kim SJ et al., Physiol Rep, 2019;7(13):e14171; USADA MOTS-c educational materials, January 2024; WADA 2026 Prohibited List; FDA Category 2 determination.
This profile will be updated as new research becomes available. Last reviewed: March 2, 2026.